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With increasing access to antiretroviral therapy (ART) in Africa, most children born to 
HIV-infected mothers are not themselves HIV-infected. These HIV-exposed, uninfected 
(HEU) children are at increased risk of mortality and have immune, growth, development, 
and health deficits compared to HIV-unexposed children. HEU children are known to be 
at higher risk than HIV-unexposed children of acquiring cytomegalovirus (CMV) infection 
in early life. This risk is largely unaffected by ART and is increased by breastfeeding, 
which itself is critically important for child health and survival. Early CMV infection, namely 
in utero or during early infancy, may contribute to reduced growth, altered or impaired 
immune functions, and sensory and cognitive deficits. We review the evidence that CMV 
may be responsible for the health impairments of HEU children. There are currently no 
ideal safe and effective interventions to reduce postnatal CMV infection. If a clinical trial 
showed proof of the principle that decreasing early CMV infection improved health and 
development of HEU children, this could provide the impetus needed for the develop-
ment of better interventions to improve the health of this vulnerable population.
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HeALTH PROBLeMS OF Hiv-eXPOSeD, 
UninFeCTeD AFRiCAn CHiLDRen
HIV-exposed, uninfected (HEU) children have always constituted the majority of children born to 
HIV-infected mothers, but until recently the focus has been on preventing mother-to-child HIV 
transmission and treating HIV-infected children, so HEU children have received little attention. 
Preventing mother-to-child HIV transmission remains crucial and the situation is improving with 
increasing provision of antiretroviral therapy (ART). As a result of decreasing infant HIV infection, 
the numbers of HEU children are rising and in high HIV prevalence countries of Southern Africa 
may account for up to 30% of births (1, 2). Thus, any health problems HEU children experience are 
of immense public health importance.
Even when HIV-infected mothers are provided with ART, their HEU infants experience numer-
ous health and development problems (3). Mortality of HEU children is increased over that of 
their HIV-unexposed counterparts (4). Compared with HIV-unexposed children, HEU children 
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have lower birth weight (5), impaired early growth (6), impaired 
psychomotor and cognitive development (7), and immune 
abnormalities (8), presumably resulting from stressors during 
in  utero or early postnatal life. The underlying causes of these 
impairments in HEU infants are probably multifactorial and 
include exposure to HIV itself (9, 10), exposure to ART (5), 
increased exposure to infections within the household (11), and 
the consequences of being born into an HIV-afflicted household, 
with impact on socioeconomic status and child care quality (4). 
The relative contribution that these different factors make to the 
health deficits of HEU children are likely to differ in different 
populations and all should be addressed.
Here, we review the evidence in support of the hypothesis 
that one potential cause, early cytomegalovirus (CMV) infec-
tion, which appears widespread across sub-Saharan Africa, is an 
important contributor to impaired health and development of 
both HIV-infected and HEU children in many African popula-
tions, and increases the risk of postnatal HIV infection. The 
synergism between HIV and CMV coinfection in African adults 
and children has been recently reviewed (12), so this article will 
focus on HEU children, in particular those in Africa where the 
burden of both CMV and HIV infection is highest.
eARLY CMv inFeCTiOn AMOnG Hiv-
eXPOSeD inFAnTS
Most African infants acquire CMV infection during infancy 
(13, 14). The risk of congenital CMV infection was higher among 
infants of HIV-infected than uninfected Zambian mothers 
(15). Increased infections with maternal HIV exposure could 
result from maternal CMV reactivation, which is common in 
HIV-infected women, particularly with low CD4 counts; CMV 
was detected in the serum and cervix of, respectively, 4.8 and 
66% ART-treated HIV-positive pregnant Kenyan women (16). 
Reduced placental transfer of maternal antibodies in HIV-
infected women (8) may also contribute to the increased risk of 
early CMV infection of their infants (17). CMV infection mainly 
occurs in African infants during the early postnatal period and a 
large proportion of CMV transmission is through breastfeeding. 
A secondary analysis of a randomized controlled trial of breast-
feeding versus formula-feeding by HIV-infected Kenyan women 
in the pre-ART era found that breastfeeding was associated with 
a significantly increased proportion of infants CMV-infected by 
age 1 year (89 versus 69% in the formula group), as well as earlier 
median acquisition of CMV infection (4.26 versus 9.87 months) 
(18). Nevertheless, as previously shown for HIV transmission in 
the Kenyan trial (19) as well as in other studies, breastfeeding 
is important for child survival and health, so switching from 
breastfeeding is not a feasible way to reduce transmission of CMV.
Currently, the World Health Organization recommends 
provision of ART during pregnancy and lactation as the best way 
of promoting HIV-free survival of infants (20). Although this 
protocol is becoming standard across Africa and is effective at 
decreasing HIV transmission, it does not appreciably alter the 
rate of African infant CMV acquisition. The rate of congenital 
CMV infection in South African infants did not differ according 
to whether their mothers had taken during pregnancy zidovudine 
only or triple-drug ART (21). Breast milk CMV load was similar 
among Malawian women who had started ART for their own 
health and women not on ART, even though the ART-treated 
women had lower plasma and milk HIV levels and both groups 
had similar CD4 counts (22). A recent study of American women 
whose ART did or did not include the protease inhibitor, nelfina-
vir, which has some ability to inhibit CMV replication, found no 
protection of nelfinavir against congenital CMV infection (23).
eFFeCTS OF eARLY CMv inFeCTiOn On 
HeALTH OF HeU CHiLDRen
Most concerns about CMV among non-HIV-exposed infants, 
particularly in the developed world, relate to congenital CMV. 
Congenital CMV arising from maternal primary or reactivated 
CMV infection during pregnancy is associated with intrauterine 
growth retardation and neurological, hearing, and vision impair-
ments in the infected infant (24, 25). In particular, 25–50% of 
infants diagnosed at birth with symptomatic congenital CMV 
(and 10% of asymptomatic congenital infections) suffer from 
hearing loss (26), which is often not detected until later in 
infancy (27). A study of CMV screening at birth for over 300 
infants born to HIV-infected mothers found that, although the 
rates of congenital CMV infection were low (10 infants, 3%), they 
were higher than usually observed in HIV-unexposed infants; 
moreover, HEU infants with asymptomatic congenital CMV 
had significantly lower birth weight and lower gestational age 
compared with infants who were CMV-uninfected at birth (28).
Whether the early postnatal CMV infection, which is common 
among HEU African infants, also has adverse effects on health 
needs to be considered. In the pre-ART era, serum CMV in HIV-
infected women at delivery was associated with almost 10-fold 
increase in maternal death and a fourfold increase in mortality 
of their HIV-infected infants by age 2  years; this remained 
statistically significant even after adjustment for maternal CD4 
count, HIV viral load, and death (29). Early CMV infection also 
results in a 2.5-fold to 4-fold increased risk of postnatal HIV 
infection (29–31), and CMV coinfection leads to more rapid 
infant HIV disease progression (29, 32). It is worth noting that 
several reports have indicated that children of HIV-positive 
mothers, both infected (33) and HEU (34), are more likely than 
their unexposed counterparts to have impaired hearing; although 
other mechanisms, including exposure to HIV itself, may have 
contributed to deafness in these children, it could well be an 
indication of congenital (or even early) CMV infection that was 
not diagnosed at birth. Because the hearing loss associated with 
congenital CMV infection is often not diagnosed until later child-
hood (particularly at school entry), it would potentially be worth 
instituting formal monitoring of the hearing of HEU infants to 
avoid the development and educational problems often faced by 
children with undiagnosed deafness.
Surviving HEU children exhibit impairments including poor 
infant growth; (6, 22) reduced psychomotor development; (7) 
and immunological abnormalities (see below). In observational 
studies, CMV infection was associated with poorer infant 
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growth (13, 22) and delayed psychomotor development (13). 
In a study in Malawi, breast milk CMV DNA viral load had a 
stronger negative association with infant growth than did milk 
HIV RNA load; the largest effects occurred in the first 4–6 weeks 
of the infant’s life, suggesting that prenatal or early postnatal 
exposure to CMV is key (22).
iMMUnOLOGiCAL COnSeQUenCeS OF 
eARLY CMv inFeCTiOn in HeU inFAnTS
In older Europeans, CMV infection is associated with frailty and 
increased mortality, predominantly through cardiovascular dis-
ease, with an estimated 47% increased risk of death compared to 
uninfected people in a large UK population of people aged 65 years 
and over (35). CMV seropositivity in the elderly is linked with a 
number of immunological features that include large expansions 
of CMV-specific T-cells with reduced naive T-cell numbers (36), 
raised C-reactive protein (37), and impaired immune responses 
to influenza vaccination (38). In contrast, CMV is acquired very 
early in life in Africa, with the majority of infections occurring 
during infancy [85% infection at one year in a Gambian birth 
cohort (14)]: the long-term consequences of early CMV acquisi-
tion in developing countries are not known.
The large CMV genome contains multiple genes linked 
with immune evasion [including the down-regulation of class 
I Histocompatibility Leukocyte Antigen (HLA) molecules, 
interference with antigen processing, suppression of T-cell 
proliferation, and production of a viral version of the immuno-
suppressive chemokine interleukin-10], which could potentially 
affect immune responses to other pathogens, although this has 
yet to be unequivocally demonstrated. Infant CMV infection 
is associated with profound changes in the phenotype of CD8+ 
and CD4+ T-cells, which show increased levels of activation 
and differentiation (39–41) similar to those described in older 
Europeans; however, there is no evidence of CMV-associated 
immune impairment in healthy infants, and vaccine responses in 
HIV-unexposed infants appear to be unaffected by CMV status, 
at least in the short term (42, 43). The overall impact of CMV 
infection on vaccine responses is not well understood: in young 
adults, CMV infection is associated with enhanced antibody and 
T-cell responses to influenza vaccination (44), but in a different 
adult cohort CMV seropositivity was linked with reduced Natural 
Killer (NK) cell responses to pertussis and H1N1 influenza 
A antigens (45). In older adults, CMV seropositivity is associated 
with significantly decreased CD4 T-cell responses to influenza 
A core antigens (38).
Although HEU infants generally show robust vaccine 
responses, at least in the short term (46), CMV infection in HEU 
infants born to Zambian HIV-infected mothers was associated 
with impaired polio vaccine responses (47). The majority of the 
immunological perturbations described in HEU infants, includ-
ing the expansion of memory T-cell subsets, reduction in naive 
T-cells, and heightened immune activation [reviewed in Ref. 
(8)], are observations consistent with and potentially explained 
by CMV infection occurring earlier in HEU children than in 
the control populations studied. Few of the published studies of 
the immunology of HEU infants have accounted for infection 
with CMV [or other herpes viruses with known impact on the 
immune system, such as Epstein–Barr virus (EBV)].
iMPACT OF MATeRnAL CMv inFeCTiOn 
On THe PLACenTA
As discussed earlier, it is not yet clear whether early CMV infec-
tion has an adverse effect on infant health in the absence of HIV 
exposure, immunosuppression, or congenital infection. Before 
the advent of CMV screening for infant blood transfusion, post-
natal transmission of CMV to premature and low birth weight 
infants was associated with a range of symptoms, including fever, 
pneumonia, hepatosplenomegaly and hepatitis, and a high risk of 
death, but these children could be regarded as immunosuppressed 
(48). However, it may also be worth considering that some of the 
abnormalities described in HEU children imply that the fetus 
faced challenges in the prenatal environment that affected the 
placenta, notably the observation of marked stunting that cannot 
be corrected by supplementary feeding in the first year of life (6) 
and the reduced transfer of maternal antibodies to the infant (49, 
50), which requires an active process by the placenta in the last tri-
mester. CMV can infect the placenta without infecting the infant, 
particularly in women with reactivated rather than primary CMV 
infection. For example, in a detailed study of the role of CMV in 
seven cases of intrauterine growth restriction, five were associated 
with CMV infection, of which three had evidence of reactivated 
infection and did not lead to in utero infection of the infant (24). 
Nevertheless, there was evidence of CMV proteins in placental 
tissue and associated pathology, such as edema and leukocyte 
infiltration, which suggests that CMV infection of the placenta 
can lead to impaired fetal growth without necessarily resulting in 
congenital infection. It was recently reported that CMV infection 
of trophoblast progenitor cells in vitro interferes with the early 
steps of the growth of placental villi and could therefore affect 
placental maturation and transport functions (51).
APPROACHeS TO DeCReASinG eARLY 
CMv inFeCTiOn OF HeU inFAnTS
Although the observational data linking early CMV infection 
with the poorer health and development of HEU African infants 
are strong, a controlled clinical trial is needed before we can 
assume that CMV infection causes these impairments. There 
is currently no ideal intervention, effective against CMV infec-
tion, safe for pregnant or lactating women and their infants, and 
feasible for use in Africa. A recent trial with a low dose (500 mg 
twice daily) of valacyclovir (GlaxoSmithKline) had no effect on 
the timing of infant CMV infection or breast milk CMV viral 
load; higher doses of the drug, as used to prevent CMV infec-
tion among transplant patients, might have had more effect but 
were considered unrealistic for pregnant and lactating women 
(17). Valganciclovir (Hoffman-La Roche) has greater anti-CMV 
effect than valacyclovir, has been used postnatally for congenital 
CMV infection (25), and led to reduced T cell activation among 
HIV-infected adults (52). However, a recent trial comparing 
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6  months versus the standard 6  weeks of valganciclovir for 
congenital CMV infection found side effects in a proportion 
of infants: 19% of infants had grade 3–4 neutropenia during 
the first 6 weeks of life that in three of 109 infants necessitated 
temporary suspension of treatment (25). A trial of hyperim-
mune globulin to prevent congenital CMV infection in infants 
of women with primary CMV infection found no significant 
decrease in congenital CMV infection, similar clinical out-
comes among congenitally infected infants, and a higher rate of 
obstetric adverse events among the women treated with globulin 
compared to those given placebo (53).
There are a number of CMV vaccines under development 
[recently reviewed in Ref. (54)]. These vaccines have largely been 
developed with the aim of preventing primary CMV infection in 
women of child-bearing age in developed countries. The risk of con-
genital CMV infection with primary infection during pregnancy 
is around 40%, whereas only 1–2% of already-infected women 
transmit CMV to their infants. Current candidate CMV vaccines 
predominantly aim to elicit neutralizing antibodies, using either 
the CMV surface glycoprotein (gB) (55), or the recently described 
pentameric complex (gH/gL/UL128-UL130-UL131) (56), which 
is required for CMV entry into epithelial cells (57). The induction 
of a strong, high avidity, neutralizing antibody response may also 
reduce congenital infection in infants of women with preexisting 
infection, but in HIV-infected women this could be impaired by 
the reduction in placental transfer of maternal antibodies that 
occurs during pregnancy. Other CMV candidate vaccines focus 
on the induction of T-cell immunity, which may have more value 
in controlling CMV reactivation in pregnancy and HIV infection. 
A phase III trial is underway in seropositive transplant recipients 
of a bivalent CMV DNA vaccine, expressing both gB and pp65, 
the main target of the T-cell response (58). In the long term, a 
vaccine that effectively prevents both congenital and early CMV 
transmission may have a major impact on the health of infants 
born to HIV-infected mothers in sub-Saharan Africa.
COnCLUSiOn AnD ReCOMMenDATiOnS
The health and development problems of HEU infants are almost 
certainly multifactorial, and this review focuses on one of these 
factors, early CMV infection. Evidence for the potential impor-
tance of early CMV infection as a contributor to poorer outcomes 
in HEU infants is increasing but is not yet definitive. The field 
now requires a clinical trial of a safe and effective anti-CMV 
intervention in order to move forward. At this juncture, a trial 
of a currently available intervention, such as valganciclovir given 
to lactating women or their infants to prevent early infant infec-
tion, would be of considerable benefit in resolving these issues. 
If such an intervention showed proof of principle that delaying 
CMV infection in HEU infants benefited their health without 
unacceptable adverse effects, this would provide impetus for the 
design of safer and more efficacious CMV interventions for this 
large and vulnerable population. Even a safe drug would increase 
the already large pill burden in HIV-infected lactating women 
or their infants so qualitative and programmatic research would 
be needed to ensure that an anti-CMV treatment was acceptable 
as well as efficacious in relevant populations. However, there is a 
precedent for adding additional drugs to ART care, specifically 
the widespread use of prophylactic Cotrimoxazole, suggesting 
that an effective anti-CMV treatment could well be similarly 
acceptable.
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